Dr. Kiavash Fekri, a pediatric hematology and oncology superspecialist, stated that for the first time in the Chaharmahal and Bakhtiari Province, two hemophilia patients were treated with the latest medication in the world, Hemlibra.

In elaborating on this news, Dr. Fekri explained that Hemlibra (emicizumab), recognized as the most advanced treatment for hemophilia globally, was administered to two patients in the thalassemia ward of the Hajar Educational and Medical Center in Shahrekord.

He emphasized that this medication is currently approved for hemophilia patients with inhibitors to Factor VIII in the country and is the first drug that does not require intravenous administration, as it is injected subcutaneously.

He continued by stating that the prolonged duration of the medication in the patient’s body can last up to one month, which is a significant feature of this drug that has the potential to revolutionize the quality of life for hemophilia patients.

He added that Hemlibra is administered subcutaneously as per the doctor's instructions, typically once a week for the first four weeks, and thereafter is prescribed according to a regular monthly schedule.

Dr. Fekri noted that this medication leads to a reduction in bleeding and allows hemophilia patients to experience a more normal life.

According to him, the introduction of this drug to the province was made possible through extensive efforts by university officials and collaboration with the Ministry of Health, especially considering its high cost, which deserves recognition and appreciation.